Gabapentin
Product Images NDC 69189-0614

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69189-0614). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 100 mg Capsule (6918906141)

Gabapentin 100 mg capsule in a white sachet packaging. The label indicates manufacturer Amneal and includes manufacturing lot number AR150620 and expiration date 04/18/2017. Hospital lot number APC16D18-AF is also shown. The labeler is Avera McKennan Hospital, Sioux Falls, SD, with NDC 69189-0614.*

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A mathematical formula calculating creatinine clearance (CLCr) based on patient's age, weight, serum creatinine level, and a factor for female patients. The formula depicts renal function estimation rather than a chemical structure.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and an acetic acid group (CH2CO2H). This is a molecular diagram representing the active ingredient gabapentin as provided by Avera McKennan Hospital.*

FDA Label Image

Figure 1 (Gabapentin Capsules Usp 3)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph also marks a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 2 (Gabapentin Capsules Usp 4)

A line graph depicting mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The X-axis represents time in weeks including a 3-week dose titration and a 4-week fixed dose period. The Y-axis shows mean pain scores from 0 to 10. Gabapentin groups show a decreasing trend in pain scores compared to placebo.*

FDA Label Image

Figure 3 (Gabapentin Capsules Usp 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares responder proportions between placebo (PBO) and different Gabapentin (GBP) doses in two studies. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400, with statistical significance indicated by asterisks for gabapentin groups.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot comparing percentage difference versus daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose in milligrams, ranging from 600 to 1800 mg, and the y-axis shows the percentage difference from 2% to 22%. Study a data points are marked in black, study b in gray, and study c in white, with each showing varying differences at specific dose levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.